Delta Jumps, Uber Rises, Eli Lilly Dips as HSBC Sees Deeper Obesity-Drug Price Cuts

Stock Movers

On this episode of Stock Movers:

- Delta (DAL) shares jump. Delta Air Lines Inc. now expects sales to grow in the high single digits through March, after previously guiding for a range of 5% to 7% growth. American Airlines Group Inc., meanwhile, said revenue in the quarter will rise more than 10% — a record for the company — even as more-expensive fuel pushes earnings projections to the more pessimistic end of its range.

-  Uber (UBER) and Lyft shares rise as the rideshare firms and Nvidia announced separate autonomous vehicle partnerships. Uber will launch a global fleet of Nvidia software-driven autonomous vehicles across 28 cities globally by 2028.

- Eli Lilly (LLY) shares dip after HSBC turned bearish on the stock, for the second time in a year, saying investor expectations for weight-loss drugs are over inflated. Analysts led by Rajesh Kumar cut the drugmaker to reduce — its sole sell-equivalent rating — from hold and slashed their price target on the stock to $850, the lowest on Wall Street.

See omnystudio.com/listener for privacy information.

More description

On this episode of Stock Movers:

- Delta (DAL) shares jump. Delta Air Lines Inc. now expects sales to grow in the high single digits through March, after previously guiding for a range of 5% to 7% growth. American Airlines Group Inc., meanwhile, said revenue in the quarter will rise more than 10% — a record for the company — even as more-expensive fuel pushes earnings projections to the more pessimistic end of its range.

-  Uber (UBER) and Lyft shares rise as the rideshare firms and Nvidia announced separate autonomous vehicle partnerships. Uber will launch a global fleet of Nvidia software-driven autonomous vehicles across 28 cities globally by 2028.

- Eli Lilly (LLY) shares dip after HSBC turned bearish on the stock, for the second time in a year, saying investor expectations for weight-loss drugs are over inflated. Analysts led by Rajesh Kumar cut the drugmaker to reduce — its sole sell-equivalent rating — from hold and slashed their price target on the stock to $850, the lowest on Wall Street.

See omnystudio.com/listener for privacy information.

2026-03-17 3 min Transcript
Listen elsewhere

Available Results

Generated results are saved to your library for reuse and search.

No generated results are available for this episode yet.

Transcript

Open the Transcript tab to load the transcript.

Chapters

No chapters available.